David L. Musso

Design of Selective and Soluble Inhibitors of Tumor Necrosis Factor-α Converting Enzyme (TACE)

Michael H. Rabinowitz, Robert Andrews, J. David Becherer et al. · Journal of Medicinal Chemistry · 2001 · 73 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17

Indanylidenes. 1. Design and Synthesis of (<i>E</i>)-2-(4,6-Difluoro-1-indanylidene)acetamide, a Potent, Centrally Acting Muscle Relaxant with Antiinflammatory and Analgesic Activity

David L. Musso, Felicia R. Cochran, James L. Kelley et al. · Journal of Medicinal Chemistry · 2002 · 60 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +10

Synthesis and evaluation of the antidepressant activity of the enantiomers of bupropion

David L. Musso, Nariman B. Mehta, Francis E. Soroko et al. · Chirality · 1993 · 40 citations

Medicine, Medicinal Chemistry, Pharmacology +17

(2<i>S</i>,3<i>S</i>,5<i>R</i>)-2-(3,5-Difluorophenyl)-3,5- dimethyl-2-morpholinol:  A Novel Antidepressant Agent and Selective Inhibitor of Norepinephrine Uptake

James L. Kelley, David L. Musso, G. Evan Boswell et al. · Journal of Medicinal Chemistry · 1996 · 40 citations

Medicine, Medicinal Chemistry, Pharmacology +10

Novel 3-phenylprop-2-ynylamines as inhibitors of mammalian squalene epoxidaseElectronic supplementary information (ESI) available: Proton NMR spectra for the intermediate piperidines 56–60 and acetylenes 63-81 and 85,86. See http://www.rsc.org/suppdata/ob/b2/b209165h/

David L. Musso, Morris J. Clarke, James L. Kelley et al. · Organic & Biomolecular Chemistry · 2003 · 30 citations

Pharmacy, Medicinal Chemistry, Pharmacology +6